About Pheast Therapeutics
Pheast Therapeutics is a private company based in Redwood City, California, incorporated in 2020 in Delaware. It has reported $99,838,083 raised in two offerings on Form D since October 2022. Its chief executive is Roy Maute.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 7, 2025 | Oct 16, 2025 | $24,588,083of $39.9M target | 7 | $3.5M | Equity, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Jan 31, 2022 | Oct 28, 2022amended Apr 10, 2025 | $75,250,000fully sold | 7 | $10.7M | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Total, two offerings | $99,838,083 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Pheast Therapeutics's Form D filed Oct 16, 2025.
IW
Irving Weissman
Director
RM
Roy Maute
CEO and director
RR
Raphael Rousseau
Executive officer
SG
Steven Gillis
Director
JV
Jacob Vogelstein
Director
AB
Amira Barkal
Director
TM
Thomas Marty
Executive officer